




ATC codes: **A03BB01**

Indication	Palliative care <b>ICD11 code: QC7A</b>
Medicine type	Chemical agent
List type	Core
Formulations	Parenteral > General injections > unspecified: 20 mg per mL injection
EML status history	First added in 2013 ( <b>TRS 985</b> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <b>about patents</b> . 
Wikipedia	<b>Hyoscine butylbromide</b> 
DrugBank	<b>Hyoscine butylbromide (Scopolamine butylbromide)</b> 

## Summary of evidence and Expert Committee recommendations

Following a review of medicines for palliative care by the Expert Committee in 2013, hyoscine butylbromide was added to the core list of the EML for management of respiratory secretions in patients receiving palliative care. Although the evidence for the benefit to the patient of the use of antimuscarinic agents in prevention of accumulation of respiratory tract secretions during the dying phase was acknowledged as weak by the Expert Committee, the inclusion of hyoscine butylbromide (which, in contrast to the hydrobromide included for children, does not cross the blood-brain barrier) was supported.

